Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Hae-Young | - |
dc.contributor.author | Chung, Wook-Jin | - |
dc.contributor.author | Jeon, Hui-Kyung | - |
dc.contributor.author | Seo, Hong-Seog | - |
dc.contributor.author | Choi, Dong-Ju | - |
dc.contributor.author | Jeon, Eun-Seok | - |
dc.contributor.author | Kim, Jae-Joong | - |
dc.contributor.author | Shin, Joon Han | - |
dc.contributor.author | Kang, Seok-Min | - |
dc.contributor.author | Lim, Sung Cil | - |
dc.contributor.author | Baek, Sang-Hong | - |
dc.date.accessioned | 2021-09-04T02:13:49Z | - |
dc.date.available | 2021-09-04T02:13:49Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2016-03 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/89387 | - |
dc.description.abstract | Background/Aims: We evaluated the association between coding region variants of adrenergic receptor genes and therapeutic effect in patients with congestive heart failure (CHF). Methods: One hundred patients with stable CHF (left ventricular ejection fraction [LVEF] < 45%) were enrolled. Enrolled patients started 1.25 mg bisoprolol treatment once daily, then up-titrated to the maximally tolerable dose, at which they were treated for 1 year. Results: Genotypic analysis was carried out, but the results were blinded to the investigators throughout the study period. At position 389 of the beta-1 adrenergic receptor gene (ADRB1), the observed minor Gly allele frequency (Gly389Arg + Gly389Gly) was 0.21, and no deviation from Hardy-Weinberg equilibrium was observed in the genotypic distribution of Arg389Gly (p = 0.75). Heart rate was reduced from 80.8 +/- 14.3 to 70.0 +/- 15.0 beats per minute (p < 0.0001). There was no significant difference in final heart rate across genotypes. However, the Arg389Arg genotype group required significantly more bisoprolol compared to the Gly389X (Gly389Arg + Gly389Gly) group (5.26 +/- 2.62 mg vs. 3.96 +/- 2.05 mg, p = 0.022). There were no significant differences in LVEF changes or remodeling between two groups. Also, changes in exercise capacity and brain natriuretic peptide level were not significant. However, interestingly, there was a two-fold higher rate of readmission (21.2% vs. 10.0%, p = 0.162) and one CHF-related death in the Arg389Arg group. Conclusions: The ADRB1 Gly389X genotype showed greater response to bisoprolol than the Arg389Arg genotype, suggesting the potential of individually tailoring beta-blocker therapy according to genotype. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.subject | SYNERGISTIC POLYMORPHISMS | - |
dc.subject | DILATED CARDIOMYOPATHY | - |
dc.subject | BLOCKER RESPONSE | - |
dc.subject | CARVEDILOL | - |
dc.subject | METOPROLOL | - |
dc.subject | PROGNOSIS | - |
dc.subject | VARIABILITY | - |
dc.subject | SURVIVAL | - |
dc.subject | COHORT | - |
dc.title | Impact of the beta-1 adrenergic receptor polymorphism on tolerability and efficacy of bisoprolol therapy in Korean heart failure patients: association between beta adrenergic receptor polymorphism and bisoprolol therapy in heart failure (ABBA) study | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Seo, Hong-Seog | - |
dc.identifier.doi | 10.3904/kjim.2015.043 | - |
dc.identifier.scopusid | 2-s2.0-84959007985 | - |
dc.identifier.wosid | 000372174600009 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.31, no.2, pp.277 - 287 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 31 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 277 | - |
dc.citation.endPage | 287 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002089195 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | SYNERGISTIC POLYMORPHISMS | - |
dc.subject.keywordPlus | DILATED CARDIOMYOPATHY | - |
dc.subject.keywordPlus | BLOCKER RESPONSE | - |
dc.subject.keywordPlus | CARVEDILOL | - |
dc.subject.keywordPlus | METOPROLOL | - |
dc.subject.keywordPlus | PROGNOSIS | - |
dc.subject.keywordPlus | VARIABILITY | - |
dc.subject.keywordPlus | SURVIVAL | - |
dc.subject.keywordPlus | COHORT | - |
dc.subject.keywordAuthor | Heart failure | - |
dc.subject.keywordAuthor | Beta-blocker | - |
dc.subject.keywordAuthor | Polymorphism | - |
dc.subject.keywordAuthor | Receptors | - |
dc.subject.keywordAuthor | adrenergic | - |
dc.subject.keywordAuthor | beta | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.